T1	Claim 1 164	Previous trials have suggested a quality-of-life (QOL) improvement for anemic cancer patients treated with erythropoietin, but few used QOL as the primary outcome.
T2	Premise 1046 1210	This revealed a significant difference in the median survival in favor of the patients on the placebo arm of the trial (63 v 129 days; hazard ratio, 1.84; P = .04).
T3	Premise 1252 1319	Patient numbers compromised the interpretation of the QOL analysis,
T4	Premise 1324 1386	a positive Hgb response was noted with epoetin alfa treatment.
T5	Claim 1387 1511	An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa.
R1	Support Arg1:T4 Arg2:T5	
R2	Partial-Attack Arg1:T3 Arg2:T5	
R3	Support Arg1:T2 Arg2:T5	
